Overview
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.
Last reviewed: 14 August 2013
We reviewed the evidence and found nothing new that affects the recommendations in this guidance. See the review decision for more details.
Diagnostics guidance 9 has been migrated to HealthTech guidance 316. The recommendations and accompanying content remain unchanged.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.